Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Drugs
Is hybridoma production about to take a quantum leap forward?
March 11th, 2008
Recently published research* has established the ability of Neowater® to enhance the various processes involved in the production of pure human monoclonal antibodies by refining the standard hybridoma production process. Biopharmaceutical companies have started to evaluate the use of fully human monoclonal antibodies as a complementary or primary therapeutic agent against a variety of diseases. The most obvious advantage would be to bypass the interference from the patient's immune system that typically characterizes the use of chemerical or humanized antibodies. Due to the growing interest and the potential benefits, the efficient production of human monoclonal antibodies is a high...
Source: Cancer Weekly (2008-03-11)
|
|
Advertisement |
|
|
|
